Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) Gross Margin (2016 - 2025)

Sanara MedTech's Gross Margin history spans 15 years, with the latest figure at 93.19% for Q4 2025.

  • For Q4 2025, Gross Margin rose 175.0% year-over-year to 93.19%; the TTM value through Dec 2025 reached 92.71%, up 210.0%, while the annual FY2025 figure was 92.71%, 210.0% up from the prior year.
  • Gross Margin reached 93.19% in Q4 2025 per SMTI's latest filing, roughly flat from 92.88% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 93.19% in Q4 2025 to a low of 82.92% in Q3 2022.
  • Average Gross Margin over 5 years is 89.67%, with a median of 90.06% recorded in 2022.
  • Peak YoY movement for Gross Margin: soared 4132bps in 2021, then tumbled -820bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 88.87% in 2021, then decreased by -5bps to 84.53% in 2022, then rose by 6bps to 89.89% in 2023, then increased by 2bps to 91.45% in 2024, then rose by 2bps to 93.19% in 2025.
  • Per Business Quant, the three most recent readings for SMTI's Gross Margin are 93.19% (Q4 2025), 92.88% (Q3 2025), and 92.5% (Q2 2025).